Wellnex Life

Wellnex Life has completed the sale of its Pain Away division to Mentholatum Australasia and has received the initial purchase price. The transaction was approved by shareholders at an extraordinary general meeting and all conditions precedent have been satisfied. Wellnex Life will continue to operate the business for liquid softgel analgesics based on its TGA approvals as well as its capital-light contract manufacturing operations. Proceeds from the sale are intended to be used to reduce debt and strengthen working capital; options to enhance shareholder value are being considered. » More on de.investing.com

Wellnex Life has entered into a binding agreement to sell the Pain Away business and assets to Mentholatum Australasia, a subsidiary of Rohto Pharmaceutical. The total consideration is up to AUD 21.3m, comprising AUD 19.8m on completion and up to AUD 1.5m in an earn-out contingent on normalised EBITDA performance in the first year after takeover. Proceeds are intended to repay around AUD 10.2m of liabilities and bolster the working capital of the remaining divisions. Due to the relative size of the business, shareholder approval under AIM rule 15 is required; an extraordinary general meeting is scheduled for 8 September 2026. » More on de.investing.com

Wellnex Life reports operating net cash flow of $63,000 for the quarter ended June 30, after $412,000 in the prior quarter; operating cash flow for the second half totaled about $500,000 versus a net outflow of $3.1 million in the first half of the year. Cash receipts were $5.7 million in the quarter ($22.0 million for the fiscal year), including about $2.4 million from a licensing partnership with Haleon; second‑half receipts were 28% higher than in the first half. Fourth‑quarter revenue rose to $7.0 million (+37.3%), gross profit to $2.0 million (+33.3%), and cash on hand increased to $862,000 (previously $217,000). The company cites partnerships with retail and pharmaceutical distributors, financing lines with Scottish Pacific and Reach Wholesale, and an extension of repayment dates for loans from former directors until the end of August 2026. » More on de.investing.com